Xeris Biopharma's Recorlev Momentum Looks Clear Until You Check the Guidance Math

Xeris Biopharma Holdings (NASDAQ: XERS) reports first-quarter 2026 earnings tomorrow morning before the market opens, with analysts expecting the company to break even on an EPS basis. The central question is whether the biopharmaceutical company can sustain the momentum from its record-breaking fourth quarter, when it posted a surprise profit and delivered revenue growth exceeding 40%, while managing increased R&D spending as it advances its pipeline toward a Phase 3 trial for XP-8121.

Part 1: Earnings Preview

Xeris Biopharma is a fast-growing biopharmaceutical company focused on developing and commercializing innovative therapies across endocrine and orphan diseases, with three commercial products: Recorlev for Cushing's syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis. The company also maintains a development pipeline led by XP-8121, a Phase 3-ready once-weekly subcutaneous injection for hypothyroidism.

Earnings Expectations: XERS reports Q1 2026 results on May 7 before market open. The consensus estimate calls for break-even EPS of $0.00 from 4 analysts, with estimates ranging from a loss of $0.03 to earnings of $0.02. The most recently reported quarter (Q4 2025) delivered actual EPS of $0.06, significantly beating the $0.03 estimate. Comparing to the same quarter last year, XERS reported a loss of $0.06 in Q1 2025, meaning the year-over-year comparison implies substantial improvement even at the break-even consensus.

Key Themes Heading Into Earnings:

Recorlev Revenue Acceleration: The Cushing's syndrome treatment delivered $45.3 million in Q4 revenue, representing 100% year-over-year growth driven by increased patient demand. With management guiding to $375-390 million in total 2026 revenue (representing over 30% growth), investors will scrutinize whether Recorlev can maintain its explosive trajectory and continue driving the company's transformation into a self-funding enterprise.

Pipeline Investment and XP-8121 Progress: Management projected R&D expenses to increase by approximately $25 million in 2026 as the company initiates its Phase 3 study for XP-8121, the once-weekly hypothyroidism treatment. Investors will look for updates on trial timelines and whether the company can balance aggressive pipeline investment with its newfound profitability, particularly given the significant SG&A increase of $45 million also projected for 2026.

Profitability Sustainability: After posting its first full-year net income of $0.6 million in 2025 and achieving Adjusted EBITDA of $59.4 million, the critical question is whether XERS can maintain profitability while ramping spending. The Q1 break-even consensus suggests a step back from Q4's $0.06 profit, and management's guidance that Adjusted EBITDA will increase in total dollars but with significantly higher expenses creates uncertainty about near-term margin trajectory.

Analysts remain overwhelmingly bullish heading into the release, with 6 of 8 analysts rating the stock a Strong Buy and a consensus price target of $11.14 implying 75% upside. However, the wide range of Q1 EPS estimates—from a $0.03 loss to $0.02 profit—reflects uncertainty about how quickly the company's investment cycle will pressure margins in the near term.

Part 2: Historical Earnings Performance

Xeris Biopharma has demonstrated a pattern of volatile earnings performance with a recent trend toward positive surprises. Over the past four quarters, the company beat estimates twice and missed twice, with surprise magnitudes ranging from -100% to +100%.

The most recent quarter (Q4 2025) delivered the strongest performance, with actual EPS of $0.06 crushing the $0.03 estimate for a +100% surprise. This marked a dramatic turnaround from Q3 2025, when the company reported break-even results against a $0.01 estimate for a -100% miss. The Q2 2025 quarter showed improvement with a loss of just $0.01 versus the expected $0.03 loss, representing a +66.67% positive surprise. Going back to Q1 2025, XERS posted a $0.06 loss compared to the $0.07 loss estimate, a +14.29% beat.

The trajectory reveals a company that has moved from consistent losses to profitability, with the magnitude of beats accelerating in recent quarters. The swing from a $0.06 loss in Q1 2025 to a $0.06 profit in Q4 2025 demonstrates the rapid transformation management has executed. However, the Q3 miss serves as a reminder that the path to sustained profitability remains uneven, particularly as the company enters a period of elevated investment spending.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

XERS typically reports before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.

Historical price behavior around earnings shows XERS is a highly volatile stock that delivers significant moves on earnings day. The average absolute Day 0 move is 8.02%, with an average intraday range of 15.46%—indicating substantial volatility even when the closing move is more modest. Day +1 follow-through averages 3.78% with a 6.95% range, suggesting continued volatility into the second session.

The most recent earnings (March 2026) saw a relatively muted -1.63% Day 0 decline despite the strong Q4 beat, with a tight 4.49% Day +1 range. However, the prior three reports delivered explosive moves: August 2025 surged +20.22% on Day 0, May 2025 jumped +15.18%, and March 2025 rose +9.55%. These large positive reactions coincided with the company's transition to profitability and accelerating revenue growth. The pattern suggests that when XERS delivers results that validate its growth narrative, the stock can move dramatically higher, while more modest reactions occur when results are already anticipated or when uncertainty about future spending increases.

Part 2.2: Options Market Expected Move

The options market is pricing an expected move of 1.33% for the upcoming earnings release, dramatically lower than the stock's historical average absolute move of 8.02% on earnings day. This suggests options traders are either underpricing potential volatility or expecting a more muted reaction compared to the explosive moves seen in prior quarters, possibly reflecting that much of the growth story is already reflected in current positioning.

Part 3: What Analysts Are Saying

Analysts maintain a strongly bullish stance on XERS heading into earnings. The consensus rating stands at 4.50 out of 5.00 (between Buy and Strong Buy), with 6 Strong Buy ratings, 0 Moderate Buys, 2 Hold ratings, and no Sell ratings among the 8 analysts covering the stock. The average price target of $11.14 implies 75% upside from the current price of $6.37, with individual targets ranging from a low of $8.00 to a high of $18.00.

Analyst sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 4.50. This stability suggests analysts are maintaining conviction in their bullish thesis despite the stock's recent performance and the upcoming transition to higher spending levels. The wide range in price targets—from $8.00 to $18.00—reflects differing views on how quickly the company can scale revenue while managing the planned $70 million increase in combined R&D and SG&A expenses for 2026. The concentration of Strong Buy ratings indicates most analysts believe the company's commercial momentum, particularly with Recorlev's 100% growth trajectory, will more than offset near-term margin pressure from pipeline and commercial investments.

Part 4: Technical Picture

The technical setup heading into earnings shows deteriorating momentum despite the stock trading above most short-term moving averages. The Barchart Technical Opinion currently registers a 40% Sell signal, representing a significant improvement from the 88% Sell reading one month ago but a slight weakening from last week's 56% Sell. This progression indicates technical pressure has eased considerably over the past month but remains in bearish territory.

Timeframe Analysis:

• Short-term (Hold): Neutral signal suggests near-term momentum has stabilized after recent weakness
• Medium-term (50% Sell): Moderate sell signal indicates intermediate-term trend remains under pressure
• Long-term (100% Sell): Strong sell signal reflects persistent weakness in the longer-term trend structure

Trend Characteristics: The trend is characterized as Weak with Weakest directional momentum, indicating a fragile technical environment heading into the earnings catalyst.

The stock is currently trading at $6.37, positioned above its 5-day ($6.27), 10-day ($6.16), 20-day ($6.12), and 50-day ($6.12) moving averages, but below its 100-day ($6.58) and 200-day ($7.07) moving averages. This configuration shows short-term relative strength but longer-term downtrend resistance overhead. The 100-day moving average at $6.58 represents immediate resistance just 3% above current levels, while the 200-day at $7.07 marks a more significant hurdle 11% higher. With the stock trading well below its longer-term averages and technical indicators showing weak directional strength, the setup is cautionary heading into earnings—any disappointment could trigger a test of the 50-day support, while a strong beat would need to clear the 100-day average to signal a meaningful technical reversal.